Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials

Cancer Treatment Reviews

Volumn 37, Issue 8, 2011, Pages 579-589

  Devriese, Lot A ^a   Voest, Emile E ^b   Beijnen, Jos H ^c,d   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Circulating tumor cells; Drug development; Early clinical trial; Pharmacodynamic biomarker; Targeted therapy; Validation

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; FIGITUMUMAB; FOCAL ADHESION KINASE; GEFITINIB; HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PANITUMUMAB; PAZOPANIB; PHARMACOLOGICAL BIOMARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA DAMAGE; DRUG TARGETING; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 80054072689     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.04.006     Document Type: Review

References (79)

1. Yap T.A., Sandhu S.K., Workman P., de Bono J.S. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010, 10(7):514-523.
2. Gutierrez M.E., Kummar S., Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009, 6(5):259-265.
3. Kummar S., Gutierrez M., Doroshow J.H., Murgo A.J. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006, 62(1):15-26.
4. Parulekar W.R., Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004, 96(13):990-997.
5. Hodgson D.R., Wellings R., Orr M.C., McCormack R., Malone M., Board R.E., et al. Circulating tumour-derived predictive biomarkers in oncology. Drug Discov Today 2010, 15(3-4):98-101.
6. Sarker D., Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007, 96:213-268.
7. Tan D.S., Thomas G.V., Garrett M.D., Banerji U., de Bono J.S., Kaye S.B., et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 2009, 15(5):406-420.
8. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95.
9. Dancey J.E., Dobbin K.K., Groshen S., Jessup J.M., Hruszkewycz A.H., Koehler M., et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010, 16(6):1745-1755.
10. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):123-134.
11. Camidge D.R., Randall K.R., Foster J.R., Sadler C.J., Wright J.A., Soames A.R., et al. Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies. Br J Cancer 2005, 92(10):1837-1841.
12. Tabernero J., Cervantes A., Rivera F., Martinelli E., Rojo F., von Heydebreck A., et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010, 28(7):1181-1189.
13. Camidge D.R., Pemberton M., Growcott J., Amakye D., Wilson D., Swaisland H., et al. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers. Cancer Chemother Pharmacol 2007, 60(4):479-488.
14. Stebbing J., Jiao L.R. Circulating tumour cells as more than prognostic markers. Lancet Oncol 2009, 10(12):1138-1139.
15. Mostert B., Sleijfer S., Foekens J.A., Gratama J.W. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009, 35(5):463-474.
16. Dotan E., Cohen S.J., Alpaugh K.R., Meropol N.J. Circulating tumor cells: evolving evidence and future challenges. Oncologist 2009, 14(11):1070-1082.
17. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351(8):781-791.
18. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12(14 Pt 1):4218-4224.
19. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(19):3213-3221.
20. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14(19):6302-6309.
21. Lianidou E.S., Mavroudis D., Sotiropoulou G., Agelaki S., Pantel K. What's new on circulating tumor cells? A meeting report. Breast Cancer Res 2010, 12(4):307.
22. US Food and Drug Administration. Guidance for industry, Bioanalytical method validation. ; 2001 [01.05.01]. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm070107.pdf.
23. European Medicines Agency. Draft guideline on validation of bioanalytical methods. ; 2009 [19.11.09]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500018062.pdf.
24. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4):366-377.
25. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101(25):9393-9398.
26. de Bono J.S., Attard G., Adjei A., Pollak M.N., Fong P.C., Haluska P., et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007, 13(12):3611-3616.
27. Hayes D.F., Walker T.M., Singh B., Vitetta E.S., Uhr J.W., Gross S., et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002, 21(5):1111-1117.
28. Cohen S.J., Alpaugh R.K., Gross S., O'Hara S.M., Smirnov D.A., Terstappen L.W., et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6(2):125-132.
29. Wang L.H., Pfister T.D., Parchment R.E., Kummar S., Rubinstein L., Evrard Y.A., et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010, 16(3):1073-1084.
30. Rossi E., Basso U., Celadin R., Zilio F., Pucciarelli S., Aieta M., et al. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 2010, 16(21):5233-5243.
31. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009, 6(6):339-351.
32. Fehm T., Becker S., Duerr-Stoerzer S., Sotlar K., Mueller V., Wallwiener D., et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007, 9(5):R74.
33. Allard W.J., Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10(20):6897-6904.
34. Riethdorf S., Fritsche H., Muller V., Rau T., Schindlbeck C., Rack B., et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007, 13(3):920-928.
35. Nagrath S., Sequist L.V., Maheswaran S., Bell D.W., Irimia D., Ulkus L., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450(7173):1235-1239.
36. Stott S.L., Lee R.J., Nagrath S., Yu M., Miyamoto D.T., Ulkus L., et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010, 2(25):25ra23.
37. Stott S.L., Hsu C.H., Tsukrov D.I., Yu M., Miyamoto D.T., Waltman B.A., et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010, 107(43):18392-18397.
38. Punnoose E.A., Atwal S.K., Spoerke J.M., Savage H., Pandita A., Yeh R.F., et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010, 5(9):e12517.
39. Lin H.K., Zheng S., Williams A.J., Balic M., Groshen S., Scher H.I., et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010, (September 28).
40. Zheng S., Lin H.K., Lu B., Williams A., Datar R., Cote R.J., et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 2010, (October 27).
41. Cao S., Li Y., Li J., Li C.F., Zhang W., Yang Z.Q., et al. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer. Oncol Rep 2010, 23(2):423-428.
42. Kallergi G., Agelaki S., Kalykaki A., Stournaras C., Mavroudis D., Georgoulias V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 2008, 10(5):R80.
43. Kallergi G., Markomanolaki H., Giannoukaraki V., Papadaki M.A., Strati A., Lianidou E.S., et al. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 2009, 11(6):R84.
44. Pachmann K., Camara O., Kavallaris A., Krauspe S., Malarski N., Gajda M., et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008, 26(8):1208-1215.
45. Hsieh H.B., Marrinucci D., Bethel K., Curry D.N., Humphrey M., Krivacic R.T., et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006, 21(10):1893-1899.
46. Payne R.E., Yague E., Slade M.J., Apostolopoulos C., Jiao L.R., Ward B., et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 2009, 10(1):51-57.
47. Shaffer D.R., Leversha M.A., Danila D.C., Lin O., Gonzalez-Espinoza R., Gu B., et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13(7):2023-2029.
48. Fehm T., Muller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010, (September 22).
49. Riethdorf S., Muller V., Zhang L., Rau T., Loibl S., Komor M., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16(9):2634-2645.
50. Pestrin M., Bessi S., Galardi F., Truglia M., Biggeri A., Biagioni C., et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009, 118(3):523-530.
51. Meng S., Tripathy D., Shete S., Ashfaq R., Saboorian H., Haley B., et al. UPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006, 103(46):17361-17365.
52. Attard G., Swennenhuis J.F., Olmos D., Reid A.H., Vickers E., A'Hern R., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69(7):2912-2918.
53. Lankiewicz S., Rother E., Zimmermann S., Hollmann C., Korangy F., Greten T.F. Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell Oncol 2008, 30(6):463-471.
54. Tewes M., Aktas B., Welt A., Mueller S., Hauch S., Kimmig R., et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009, 115(3):581-590.
55. Flores L.M., Kindelberger D.W., Ligon A.H., Capelletti M., Fiorentino M., Loda M., et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 2010, 102(10):1495-1502.
56. Jiang Y., Palma J.F., Agus D.B., Wang Y., Gross M.E. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010, (June 25).
57. Roock W.D., Vriendt V.D., Normanno N., Ciardiello F., Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2010, (December 14).
58. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4(7):505-518.
59. Molife L.R., Fong P.C., Paccagnella L., Reid A.H., Shaw H.M., Vidal L., et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751, 871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010, 103(3):332-339.
60. Di Lorenzo G., Buonerba C., Autorino R., De Placido S., Sternberg C.N. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010, 70(8):983-1000.
61. Leversha M.A., Han J., Asgari Z., Danila D.C., Lin O., Gonzalez-Espinoza R., et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009, 15(6):2091-2097.
62. Swennenhuis J.F., Tibbe A.G., Levink R., Sipkema R.C., Terstappen L.W. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 2009, 75(6):520-527.
63. Cummings J., Ward T.H., Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today 2010, 15(19-20):816-825.
64. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331(6024):1559-1564.
65. Marrinucci D., Bethel K., Bruce R.H., Curry D.N., Hsieh B., Humphrey M., et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007, 38(3):514-519.
66. Bonnomet A., Brysse A., Tachsidis A., Waltham M., Thompson E.W., Polette M., et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 2010, 15(2):261-273.
67. Sieuwerts A.M., Kraan J., Bolt J., van der Spoel P., Elstrodt F., Schutte M., et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009, 101(1):61-66.
68. Mostert B., Kraan J., Bolt-de Vries J., van der Spoel P., Sieuwerts A.M., Schutte M., et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2010, (April 9).
69. Vona G., Sabile A., Louha M., Sitruk V., Romana S., Schutze K., et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000, 156(1):57-63.
70. Hou J.M., Krebs M., Ward T., Sloane R., Priest L., Hughes A., et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 2011, 178(3):989-996.
71. Theodoropoulos P.A., Polioudaki H., Agelaki S., Kallergi G., Saridaki Z., Mavroudis D., et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010, 288(1):99-106.
72. Danila D.C., Heller G., Gignac G.A., Gonzalez-Espinoza R., Anand A., Tanaka E., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13(23):7053-7058.
73. Krebs M.G., Sloane R., Priest L., Lancashire L., Hou J.M., Greystoke A., et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011, (March 21).
74. Kraan J., Sleijfer S., Strijbos M.H., Ignatiadis M., Peeters D., Pierga J.Y., et al. External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin Cytom 2010, (November 10).
75. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131(1):18-43.
76. US National Institutes of Health. [accessed 11.01.11]. http://www.clinicaltrials.gov.
77. Goulart B.H., Clark J.W., Pien H.H., Roberts T.G., Finkelstein S.N., Chabner B.A. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007, 13(22 Pt 1):6719-6726.
78. Glassman R.H., Ratain M.J. Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther 2009, 85(2):134-135.
79. Smirnov D.A., Zweitzig D.R., Foulk B.W., Miller M.C., Doyle G.V., Pienta K.J., et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65(12):4993-4997.